Latest news with #AbrarMir
Economic Times
17-06-2025
- Business
- Economic Times
HealthQuad targets raising $300 million third fund to back healthcare tech startups
ETtech (L-R) Sunil Thakur, Abrar Mir and Amit Varma, cofounders, HealthQuad Healthcare venture capital firm HealthQuad is raising $300 million (Rs 2,527.5 crore) for its third India-focussed fund. The firm, backed by Quadria Capital, an Asia-focussed private equity fund specialising in healthcare, plans a corpus of $200 million with an additional $100 million greenshoe option to fund healthcare enterprise innovation startups in India. Founded in 2016 under the Quadria Group, HealthQuad has focussed on backing tech-enabled healthcare models at the early-growth firm's first two funds backed over 18 companies, including Medikabazaar, THB, Wysa, Ekincare, Redcliffe Labs, GoApptiv, and Strand Life Sciences. This announcement comes in the wake of a split between HealthQuad's leadership team and Kois, the Belgian firm that co-founded HealthQuad alongside Quadria Capital. Following the departure of a general partner, the individual has launched a new healthcare venture capital fund of similar size, named HealthKois. 'We continue to own funds I and II fully under Quadria,' Sunil Thakur, cofounder and investment committee member at HealthQuad, told ET. The new fund will focus on companies solving operational challenges for hospital chains. "We are looking to fund 13-15 companies in this fund," said fund will tap into Quadria Group's extensive Asia network and institutional relationships to drive growth in portfolio company Quadria Capital recently raised $1.07 billion for its third fund, demonstrating strong investor appetite for the group's strategy.
Time of India
17-06-2025
- Business
- Time of India
Quadria Group launches HealthQuad Fund III to improve healthcare accessibility
New Delhi / Mumbai: Healthcare-focused Private equity firm Quadria Group has announced the launch of HealthQuad Fund III . The new fund has a target corpus of $200 million, with an additional $100 million greenshoe option. HealthQuad Fund III follows two earlier funds that supported early-stage, tech-enabled healthcare ventures in India. The stated aim of the fund is to continue investing in models that improve access, affordability, and quality of care. HealthQuad was launched in 2016 as a separate investment vehicle within Quadria to focus on early-growth healthcare innovations. As part of the latest development, Quadria Group states it will take full ownership of the HealthQuad platform following its separation from KOIS. Dr. Amit Varma, Abrar Mir, and Sunil Thakur will lead the platform, and most existing investment and investment committee team members will remain involved with the portfolio. Quadria also indicates plans to expand the team with new hires from investment, operations, and clinical backgrounds, to be announced shortly.
Business Times
09-06-2025
- Business
- Business Times
Asia healthcare assets risk overvaluation as private investors scoop them up
[SINGAPORE] As private equity (PE) investors pour money into Asian healthcare, some observers are concerned that this sector could soon overheat. Some recent deals this year include KKR's US$400 million purchase of a 54 per cent stake in India's Healthcare Global Enterprises in February. In Singapore, another American PE firm TPG took Catalist-listed nursing operator Econ Healthcare private in a deal worth nearly S$88 million. When the proposed transaction was announced in February, the offer price represented a 20 per cent premium to Econ's last traded share price on Jan 14. 'We are not the only ones to see the opportunity of healthcare in Asia, and, as a consequence, valuations can be high,' Abrar Mir, co-founder and managing partner of healthcare-focused PE firm Quadria Capital, told The Business Times. Other factors driving investors to the healthcare sector – perceived as defensive, and so able to withstand the ups and downs of economic cycles – is the ongoing macroeconomic uncertainty and volatility in global financial markets. This is particularly so in Asia, where investors have been diversifying away from China in the last few years, to avoid being caught in the cross hairs of the nation's tensions with the United States. As PE firms and their investors focus on acquiring companies independent of China, more deals have been transacted in Japan, South Korea and India, where the demand for healthcare and related services is strong and largely unaffected by tariffs. 'Japan has always been a stable healthcare market, and particularly because of (its) demographics and medical needs,' said David Braga Malta, thematic health principal at Pictet Alternative Advisors, to BT. 'We saw some of the mid-sized Japanese pharma companies being very acquisitive in the recent months and years... And of course, we saw the boom in the IPO (initial public offering) markets in India last year.' BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Asia's appeal even drew European PE investors to buy South Korean assets for the first time in 2024, he added. Last September, France's Archimed spent US$742 million buying Jeisys Medical, a South Korean developer of aesthetic medicine devices. Like shopping in Louis Vuitton 'One of the key things that I always say to my investors is that... investing in healthcare in Asia is like shopping in Louis Vuitton. So, as an investor, we have to navigate that, be careful not to overpay,' said Quadria Capital's Mir. According to a Bain & Co report, global PE deal value in the sector surged last year to an estimated US$115 billion – the second highest on record. Bain added that PE firms continue to invest in healthcare in the Asia-Pacific, where deal values have been steadily rising since 2016. Industry participants named India as the country attracting the most number of healthcare PE investors. An ageing population, rising incidence of chronic disease and growing awareness of preventive care, combined with the opening up of its insurance market to foreign investment, are making India stand out. Bain estimated that the country made up 26 per cent of the 62 deals transacted in the Asia-Pacific last year. PwC said its health industries practice in India hit a double-digit compound annual growth rate in the past few years as well. But Ling Tok Hong, deals and private equity leader at PwC, cautioned that 'this continued focus on the India market could make it more susceptible to overvaluation if investors are not cautious'. South-east Asia's healthcare sector is also attracting PE investors, leading to 'unprecedented valuations' of Ebitda multiples in their 20s, noted Ling. He was referring to earnings before interest, taxes, depreciation and amortisation. Room for growth; returns still strong Despite the rising valuations in Asia's healthcare sector, market participants point out that there is still room for growth, a key factor backing the higher valuations in the first place. The sector offers attractive long-term growth prospects as the supply of quality healthcare assets in the region is not growing quickly enough to meet demand. In markets such as South-east Asia, 'the number of large, institutionally ready platforms is still limited. This scarcity has helped sustain high entry multiples in recent years', said Alex Boulton, partner and Asia-Pacific lead for healthcare and life sciences private equity at Bain. He pointed out that South-east Asia's healthcare sector relies heavily on private players. For instance, the private sector accounts for roughly half of all hospital beds in Indonesia and the Philippines. 'That structural dynamic creates an enduring role for private capital in expanding and upgrading healthcare infrastructure.' Market participants emphasise that Asian healthcare is not in bubble territory. Boulton pointed out that even with rising valuations, healthcare PE in Asia is still delivering strong returns. Bain's analysis shows that from 2018 to 2023, the median multiple on invested capital (MOIC) for exited healthcare deals in the region was approximately 2.6 – meaning that a US$1 million investment generated a return of US$2.6 million. This compares with the global median MOIC of around two. 'That speaks to the sector's ability to compound value through growth and operational improvement, even in a more expensive entry environment,' noted Boulton. That said, while returns are likely to remain strong in the future, the median MOIC may not be sustained at these levels, he added. Thus, market players said, investors will need to have a clear plan to create meaningful impact and value over the life of their investments.
Yahoo
27-05-2025
- Business
- Yahoo
Quadria Capital closes Fund III fundraising round to advance healthcare at $1.07bn
Singapore-based private equity company Quadria Capital has closed its Fund III fundraising round, which aimed to raise capital to "transform" healthcare across Asia. The fundraising round has secured a total of $1.07bn in commitments and surpassed its original goal of $800m. It is 60% larger than the company's previous fund, which was held in 2020 and raised $600m. The oversubscribed Fund III includes more than $954m in primary commitments and $114m in committed co-investment capital. The total capital pledged is forecast to approach approximately $1.3bn once fully allocated, anticipating a further $300m in co-investment potential during the investment period. Quadria Capital co-founder and managing partner Abrar Mir said: 'Fund III's close, amid one of the most demanding fundraising climates in recent memory, is a powerful validation of our strategy and our mission. 'It reflects deep global investor conviction in the transformational opportunity in Asian Healthcare, where social impact and financial performance go hand in hand.' Quadria Capital has received support from its largest existing backers, which include North American and European sovereign wealth funds, strategic corporates and asset managers. The fund has additionally received pledges from institutional backers and support from the Gulf Cooperation Council (GCC) nations, including Saudi Arabia, the United Arab Emirates and Bahrain. Indian investors, including banks, insurance companies and family offices, have also shown interest and contributed capital. Quadria Capital said the fundraising round positions it for structural growth in Vietnam, where the healthcare market is currently worth $25bn. The company claims its investment in FV Hospital, one of the country's largest healthcare providers, has led to "major clinical improvements and substantial enhancements in patient outcomes". Last year, Quadria Capital was in advanced discussions to acquire a minority stake in NephroPlus, an India-based dialysis chain, for around Rs20bn ($250m). "Quadria Capital closes Fund III fundraising round to advance healthcare at $1.07bn" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
New Indian Express
27-05-2025
- Business
- New Indian Express
Quadria's oversubscribed fund: What it signals for Asia's healthcare industry
'It reflects the strong global investor confidence in the transformational opportunity within Asian healthcare, where social impact and financial performance go hand in hand,' confirms Abrar Mir, co-founder and managing partner at Quadria Capital. Quadria Capital said in a statement on Tuesday that Fund III drew support from prominent sovereign wealth funds, asset managers, and strategic corporates across North America and Europe. It also secured new commitments from globally recognised institutional investors, with notable participation from leading institutions in the GCC—including Saudi Arabia, the UAE, and Bahrain. In India, the Fund attracted new capital from major banks, insurance companies, and family offices. Additionally, robust re-up commitments from impact investors reaffirm Quadria's dedication to building scalable, high-impact healthcare businesses that deliver lifesaving care to underserved populations across Asia. Asian Healthcare Scenario Currently Asia's healthcare market is estimated to be $5 trillion, and the healthcare industry is reportedly at a pivotal inflection point and will remain a focal area into 2025. "In India, particularly, we're seeing significant investment interest in single-specialty hospitals, diagnostics, medical devices, and pharmaceutical manufacturing—including active pharma ingredients (APIs) and contract (drug) development and manufacturing (CDM). These segments are poised for growth due to increasing healthcare consumption, cost-efficiency initiatives, and deeper technology integration," says Dr Amit Verma, co-founder and managing partner, Quadria Capital. Healthcare growth funds like Quadria's typically provide the industry with strategic guidance and operational support to help scale their businesses and achieve market leadership. Quadria claims that nearly 40% of Fund III is already deployed. Its current investments include Aragen Life Sciences (a global CRDMO serving 400+ pharmaceutical clients), NephroPlus (Asia's largest dialysis chain), and Maxivision (India's leading eye care chain). Two new investments in Southeast Asia are expected shortly, it says. India Impact India is rapidly emerging as a strategic hub for global pharmaceutical and MedTech manufacturing as supply chains diversify, especially with the China plus strategy. While the per capita healthcare spending in India remains low at just $74—far below regional peers like Thailand (US$364) and Malaysia (US$487)—with nearly 50% of healthcare costs still paid out-of-pocket, the healthcare focused funds can catalyse Indian healthcare innovation by strategically investing in high-growth areas such as specialised care and pharmaceutical manufacturing, aiming to create scalable, affordable healthcare solutions for over a billion people.
